BMS’ Opdivo Receives the CHMP’s Positive Opinion as a Neoadjuvant Treatment of Resectable NSCLC
Shots:
- The CHMP has recommended Opdivo + Pt-based CT as neoadj. followed by Opdivo alone as adj. treatment of adults with resectable NSCLC at high risk of recurrence & PD-L1 expression ≥1%. If approved, EC’s decision would be valid in all 30 EEA states
- The P-III (CheckMate-77T) study assessed neoadj. Opdivo + CT, followed by surgery & adj. Opdivo alone vs CT & PBO in 461 pts with resectable stage IIA to IIIB NSCLC
- Trial showed improved EFS (1EP), along with improvements in 2EPs of pCR & major pathologic response (MPR), while OS remains under assessment; data was presented at ESMO congress 2023 & published in The NEJM
Ref: BMS | Image: BMS
Related News:- BMS Reports the EC’s Approval of Breyanzi to Treat R/R Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
